Evidence map›Paper›PMID 30514153›Full record

ArticleCancer biology & therapy2019

2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol reverses EGF-induced cell migration and invasion through down-regulation of MDM2 in breast cancer cell lines.

Dayong Zheng, Xing Chang, Yang Liu, Jingwen Xu, Wenfeng Gou, Zengqiang Li, Daiying Zuo, Weige Zhang, Yingliang Wu

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Dayong Zhenga Department of Pharmacology , Shenyang Pharmaceutical University , Shenyang , China.
Xing Changa Department of Pharmacology , Shenyang Pharmaceutical University , Shenyang , China.
Yang Liua Department of Pharmacology , Shenyang Pharmaceutical University , Shenyang , China.
Jingwen Xua Department of Pharmacology , Shenyang Pharmaceutical University , Shenyang , China.
Wenfeng Goua Department of Pharmacology , Shenyang Pharmaceutical University , Shenyang , China.
Zengqiang Lia Department of Pharmacology , Shenyang Pharmaceutical University , Shenyang , China.
Daiying Zuoa Department of Pharmacology , Shenyang Pharmaceutical University , Shenyang , China.
Weige Zhangb Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education , Shenyang Pharmaceutical University , Shenyang , China.
Yingliang Wua Department of Pharmacology , Shenyang Pharmaceutical University , Shenyang , China.
Shenyang Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol (SQ), a novel synthesized combretastatin A-4
(CA-4) analogue, is identified as a microtubule inhibitor and has been shown to exert anticancer activity in breast cancer cells. Here, we found that SQ reversed epidermal growth factor (EGF)-induced motility and invasion in breast cancer cell lines by the in vitro Wound healing and Transwell assay. Further studies showed that SQ treatment resulted in inhibitory alteration of EGF-stimulated epithelial-to-mesenchymal transition (EMT) and MMP-2 activity. What is more, SQ significantly inhibited the EGF-induced mouse double minute 2- (MDM2) expression and transcription factor Twist1 expression. In addition, compared with the control cells, MDM2 overexpression up-regulated Twist1 expression and dramatically promoted cell migration and invasion, MDM2 under-expression also down-regulated Twist1 expression and suppressed cell motility and invasion. Taken together, our findings suggest that the inhibitory effects of SQ on migration and invasion were related to the suppression of MDM2 and Twist1 signal axis.

Indexed as

ApoptosisBreast NeoplasmsCell AdhesionCell MovementCell ProliferationEpidermal Growth FactorFemaleGene Expression Regulation, NeoplasticHumansNeoplasm InvasivenessOrganoselenium CompoundsProto-Oncogene Proteins c-mdm2Tumor Cells, CulturedWound Healing2-methoxy-5-((3,4,5-trimethosyphenyl)seleninyl)phenolEpidermal Growth FactorMDM2 protein, humanOrganoselenium CompoundsProto-Oncogene Proteins c-mdm2Combretastatin A-4 analogueEMTinvasionMDM2migrationTwist1

Identifiers

PMID30514153
PMCPMC6422509
OpenAlexW2903352887

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.